Navigation Links
Analysis Shows Lamictal As An Effective Additional Therapy For Treatment of Grand Mal Seizures

Researchers have shown the effectiveness of Lamictal (lamotrigine) as additional treatment method in children and young people with primary// generalized tonic-clonic (PGTC) seizures.

According to the latest issue of the journal Paediatrics, lamotrigine (LAMICTAL) has been demonstrated to be effective as an additional therapy for the treatment of Primary Generalized Tonic-Clonic (PGTC) seizures, in children and adolescents. It was explained that this research analysis is the first published data from a random, double blind, controlled clinical trial of PGTC seizures mainly concentrating on patients between the age group of 2 to 20 years. It was explained that 1C PGTC seizures, which are commonly know as "grand mal" seizures, are the most common form of generalized seizures, that occur in approximately 20% of patients with epilepsy. It was also mentioned that Lamictal is not presently indicated for the treatment of PGTC seizures.

'PGTC seizures are more common in children than in adults, and are associated with increased risk of injury or death,' said Edwin Trevathan, M.D., M.P.H., Director of the Division of Paediatric and Developmental Neurology at Washington University School of Medicine and Neurologist-in-Chief, St. Louis Children's Hospital, St. Louis, MO, key investigator of the clinical study. “These study findings are important since physicians and neurologists continue to have limited treatment options available for generalized seizures in this age group.”

PGTC seizures usually occur without warning and are associated with wide-ranging physical and behavioural changes with potentially life-threatening complications.

Patients who experience PGTC seizures become stiff, lose consciousness, and jerk repetitively. Patients may fall to the ground, bite their tongue, and/or lose bladder control. Serious injury including bone fractures can occur. The seizure will typically last for a few minutes and then be followed b y a period of drowsiness, confusion, headache, and sleep. For some people who have this type of seizure, it can take many hours to fully recover.

ABOUT THE STUDY
A randomised, double blind, placebo-controlled study was conducted to assess the efficacy and tolerability of adjunctive therapy with LAMICTAL in the treatment of PGTC seizures among patients 2 years of age and older. Investigators evaluated 117 patients, ages 2-55 years, with PGTC seizures inadequately controlled on 1-2 current AEDs and with evidence of PGTC seizures on electroencephalogram (EEG) and no past evidence of partial seizures. The treatment period consisted of an Escalation phase (7-12 weeks) and a Maintenance phase (12 weeks).

In a subgroup analysis of 45 patients 2-20 years of age, the median percent decrease from Baseline in PGTC seizures during the entire treatment period was 77 percent among patients receiving LAMICTAL and 40 percent in the placebo group (p=0.044). The median PGTC seizure counts per month were significantly improved for all treatment phases in patients receiving LAMICTAL compared to placebo.

The most commonly reported adverse events in this analysis were headache (10% LAMICTAL, 25% placebo), nasopharyngitis (14% LAMICTAL, 4% placebo), and convulsion (10% LAMICTAL, 17% placebo). One patient from each treatment group discontinued due to an adverse event. No serious rashes occurred among patients taking LAMICTAL or placebo. No patient experienced worsening of myoclonus.

Overall, adjunctive therapy with LAMICTAL appeared to be effective in controlling PGTC seizures among patients 2 to 20 years of age and was associated with a favourable tolerability profile.

ABOUT EPILEPSY
Epilepsy, defined by recurrent unprovoked seizures, is a change in sensation, awareness, or behaviour brought about by an electrical disturbance in the brain. The kind of seizure a person has depends on which part and how much of the brain is affected by the disturbance that produces seizures. Generalized seizures are seizures that involve the entire brain from the outset. In most cases, the cause of epilepsy is unknown. According to the Epilepsy Foundation, epilepsy affects more than 2.5 million people in the United States of all ages.

Source: EurekAler.
'"/>




Related medicine news :

1. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
2. Meta Analysis Links Diabetes And Colorectal Cancer
3. NASA Analysis Say 2005 Was The Warmest Year
4. First Suspected Bird Flu Case In Serbia: Samples Sent For Analysis
5. A Detail Analysis of Head and Neck Cancer
6. Analysis: Bowel Diseases Triples Infertility Risks In Women
7. Analysis of Placenta Helps In Diagnosis of Autism At Birth
8. Salivary Analysis for Early Detection of Breast Cancer
9. Severe Complications of Circumcision: An Analysis of 48 Cases
10. Experimental treatment for Ebola Virus Shows promising results in mice
11. New Prostate Cancer Vaccine Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... Berkeley, and other leading institutions in announcing the launch of the Leadership ... the way animals are raised for food. , Founding members of the Leadership ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... biologics manufacturer, has expanded its executive staff with the addition of industry sales ... this role, Slott will develop the national distribution and sales network, direct the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
Breaking Medicine Technology: